Definition and epidemiology
Catatonia is a syndrome, not a single disease, characterized by abnormal motor behavior arising from an underlying psychiatric, neurologic, metabolic, or toxic disturbance of brain function. It can occur with hypoactivity (stupor), hyperactivity (excitement), or mixed features, and in a severe autonomic form called malignant catatonia.
- Prevalence among acute psychiatric inpatients is roughly 5-10%, higher in some series.
- Most commonly associated with mood disorders (major depression, bipolar disorder) rather than schizophrenia, despite the historical ICD/DSM association with psychosis.
- Also seen with autism spectrum disorder, general medical conditions (encephalitis, autoimmune/anti-NMDA receptor encephalitis, metabolic derangements), and drug intoxication or withdrawal.
- Occurs across all ages, including children and the elderly; no strong sex predilection.
- DSM-5 reclassified catatonia as a specifier that can be attached to any psychiatric diagnosis, or coded as catatonia due to another medical condition, rather than only a subtype of schizophrenia (the F20.2 ICD-10 label reflects older nosology).
- Catatonia requires at least 3 of 12 characteristic signs: stupor, mutism, waxy flexibility, negativism, posturing, stereotypy, mannerisms, agitation, grimacing, echolalia, echopraxia, catalepsy.
- Most commonly associated with mood disorders, not schizophrenia, despite the historical ICD label F20.2.
- Lorazepam challenge is both diagnostic (rapid improvement) and first-line therapeutic.
- Avoid antipsychotics in acute catatonia; they can precipitate malignant catatonia/NMS.
- Malignant catatonia = catatonia + autonomic instability (fever, tachycardia, labile BP) = medical emergency.
- ECT is first-line for malignant catatonia and for benzodiazepine-nonresponders.
- Anti-NMDA receptor encephalitis is an important reversible cause, especially in young patients with new psychiatric symptoms plus neurologic signs.
- Bush-Francis Catatonia Rating Scale is the standard bedside screening/severity tool.
Etiology and risk factors
Psychiatric causes
- Mood disorders: major depressive disorder, bipolar disorder (most common association)
- Schizophrenia and other primary psychotic disorders
- Autism spectrum disorder and other neurodevelopmental disorders
Medical and neurologic causes
- Autoimmune/paraneoplastic encephalitis, especially anti-NMDA receptor encephalitis
- Infections (viral encephalitis, HIV)
- Metabolic derangements (hyponatremia, hepatic or uremic encephalopathy, hypercalcemia)
- Structural brain lesions (frontal, parietal, or basal ganglia pathology)
Toxic/drug-related causes
- Abrupt withdrawal of benzodiazepines or clozapine
- Neuroleptic malignant syndrome (overlaps clinically with malignant catatonia)
- Intoxication with phencyclidine, cannabis, or other substances
Risk factors include prior catatonic episodes, severe mood or psychotic illness, and recent discontinuation of GABAergic medications.
Pathophysiology
The pathophysiology is incompletely understood but centers on dysregulation of GABA, glutamate, and dopamine signaling in cortical-subcortical motor circuits (orbitofrontal cortex, basal ganglia, thalamus).
- A leading hypothesis proposes reduced GABA-A receptor activity in the orbitofrontal and motor cortex, producing the characteristic immobility, mutism, and rigidity; this explains the dramatic response to GABA-A agonists such as lorazepam.
- Excess glutamatergic (NMDA receptor-related) activity is also implicated, consistent with the catatonia seen in anti-NMDA receptor encephalitis and the therapeutic effect of NMDA antagonists like amantadine in some refractory cases.
- Dopaminergic dysregulation links catatonia to neuroleptic malignant syndrome; both share a final pathway of basal ganglia dysfunction and autonomic instability in their malignant forms.
- Malignant catatonia and NMS likely represent related end-states of extreme motor circuit dysfunction with superimposed autonomic storm, explaining overlapping fever, rigidity, and rhabdomyolysis.
Clinical features
Diagnosis requires at least three of the following motor/behavioral signs, which can be elicited on bedside exam.
Core signs
- Stupor: no psychomotor activity, not actively relating to environment
- Catalepsy / waxy flexibility: limb maintains imposed posture against gravity, with slight resistance like bending a candle
- Mutism: absent or minimal verbal response
- Negativism: opposition or no response to instructions or external stimuli
- Posturing: spontaneous maintenance of an unusual posture against gravity
- Mannerisms: odd, exaggerated caricatures of normal actions
- Stereotypy: repetitive, non-goal-directed movements
- Agitation: excessive motor activity unrelated to external stimuli (excited catatonia)
- Grimacing, echolalia (repeating others' speech), echopraxia (mimicking others' movements)
Malignant catatonia
Adds autonomic instability: fever, tachycardia, labile blood pressure, diaphoresis, and risk of rhabdomyolysis, renal failure, and death if untreated. This is a medical emergency and overlaps clinically with neuroleptic malignant syndrome and serotonin syndrome.
Diagnosis
Catatonia is a clinical diagnosis based on bedside observation and a structured rating scale, supplemented by workup for the underlying cause.
- Screening/confirmation: Bush-Francis Catatonia Rating Scale (BFCRS), the most widely used standardized tool; a score threshold on the screening items plus the lorazepam challenge supports the diagnosis.
- Lorazepam challenge test: intravenous or intramuscular lorazepam produces marked, often immediate improvement in catatonic signs within minutes to hours; this response is both diagnostic and the basis for initial treatment.
- Laboratory workup: complete metabolic panel, creatine kinase (elevated in malignant catatonia/rhabdomyolysis), thyroid function, inflammatory markers, and toxicology screen.
- Neuroimaging: brain MRI to exclude structural lesions, especially in first-episode or atypical presentations.
- EEG: helpful to exclude nonconvulsive status epilepticus, which can mimic catatonic stupor.
- Autoimmune workup: anti-NMDA receptor and other autoimmune encephalitis antibody panels, lumbar puncture with CSF analysis, particularly in young patients or those with new neurologic signs, seizures, or atypical psychiatric presentation.
No single lab test confirms catatonia; the diagnosis rests on the clinical exam plus a positive benzodiazepine challenge.
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Neuroleptic malignant syndrome | History of antipsychotic exposure, lead-pipe rigidity, less responsive to benzodiazepines, usually requires dantrolene/bromocriptine |
| Serotonin syndrome | Recent serotonergic drug exposure, hyperreflexia and clonus (vs. rigidity), rapid onset |
| Locked-in syndrome | Preserved vertical eye movements and consciousness, due to pontine lesion, no response to lorazepam |
| Nonconvulsive status epilepticus | Confirmed by EEG, may require antiepileptic rather than benzodiazepine-sparing approach |
| Severe depression with psychomotor retardation | Overlaps with catatonia; depressive stupor may itself be a form of catatonia |
| Encephalopathy (metabolic/toxic) | Fluctuating consciousness, abnormal labs, no classic waxy flexibility |
| Parkinsonism/extrapyramidal syndromes | Rigidity and bradykinesia but typically no mutism or negativism, tremor present |
Management
Treatment targets both the catatonic syndrome itself and any identifiable underlying cause; benzodiazepines and electroconvulsive therapy (ECT) are the mainstays across guidelines.
First-line
- Benzodiazepines (lorazepam): first-line for all catatonia subtypes; most patients show significant improvement, and the dose is titrated to response.
- Discontinue or avoid antipsychotics initially, since they can worsen catatonia and precipitate malignant catatonia or neuroleptic malignant syndrome, especially high-potency first-generation agents.
If benzodiazepine-refractory
- Electroconvulsive therapy (ECT): highly effective, considered first-line for malignant catatonia and for benzodiazepine-nonresponders; also preferred when rapid resolution is needed (e.g., malignant catatonia, pregnancy, or marked medical compromise).
Malignant catatonia
- Treated as a medical emergency: ICU-level supportive care, aggressive hydration, cooling for hyperthermia, and urgent ECT; benzodiazepines are used while arranging ECT.
- Antipsychotics are generally avoided until catatonia resolves; if psychosis later needs treatment, atypical agents are introduced cautiously after catatonic signs clear.
Adjunctive/refractory options
- NMDA antagonists (amantadine, memantine) have been used in treatment-resistant cases, with variable evidence.
- Treat the underlying cause: immunotherapy for autoimmune encephalitis, correction of metabolic derangements, discontinuation of offending drugs.
Guideline consensus (APA, major European and WHO-aligned practice) agrees on benzodiazepines first and ECT for refractory or malignant cases; specific second-line agents vary more by local practice and evidence strength.
Complications and prognosis
- Malignant catatonia carries significant mortality if untreated, from autonomic instability, rhabdomyolysis, renal failure, and venous thromboembolism from prolonged immobility.
- Prolonged immobility also predisposes to deep vein thrombosis/pulmonary embolism, pressure ulcers, aspiration pneumonia, dehydration, and malnutrition.
- With prompt recognition and treatment (benzodiazepines, ECT when needed), prognosis is generally good, with most patients achieving substantial or complete resolution of catatonic signs.
- Recurrence is possible, especially if the underlying psychiatric or medical disorder is not adequately treated or if the catatonia was triggered by an identifiable removable cause (e.g., drug withdrawal) that recurs.
- Long-term outcome depends heavily on the underlying etiology (e.g., autoimmune encephalitis vs. primary mood disorder) rather than catatonia itself.
WARM MEN: Waxy flexibility, Agitation/excitement, Rigidity, Mutism, Mannerisms, Echolalia/echopraxia, Negativism — core catatonic signs to screen for at the bedside.
Practice questions
1. A 34-year-old woman with a history of major depressive disorder is brought to the emergency department by family after 3 days of not speaking or eating. On exam, she is immobile, does not respond to questions, and when her arm is lifted it remains suspended in the air for over a minute. Vital signs are normal. Which of the following is the most appropriate initial step?
2. A 22-year-old man with schizophrenia develops catatonic stupor that initially improved with lorazepam but now, on hospital day 4, he develops fever of 39.4°C, tachycardia, labile blood pressure, and diaphoresis along with worsening rigidity. Creatine kinase is markedly elevated. Which of the following is the most appropriate next step in management?
3. A 19-year-old woman presents with a 2-week history of bizarre behavior, auditory hallucinations, and now mutism with posturing. She also has new-onset seizures and orofacial dyskinesias. MRI is unremarkable. Which of the following is the most appropriate next diagnostic step?
Frequently asked questions
What causes catatonia?
Catatonia results from dysregulated GABA, glutamate, and dopamine signaling in cortical-motor circuits, most often triggered by an underlying mood disorder, schizophrenia, autoimmune encephalitis, metabolic derangement, or drug intoxication/withdrawal. Mood disorders, particularly depression and bipolar disorder, are the most common associated psychiatric illness. Identifying the trigger matters because treating the underlying cause, alongside benzodiazepines, improves outcomes.
What are the first symptoms of catatonia?
Early signs often include mutism, immobility or stupor, odd fixed postures, and reduced responsiveness to the environment, sometimes alternating with episodes of purposeless agitation. Family or staff may first notice the patient staring blankly, not eating or drinking, or holding unusual positions for prolonged periods. These signs can develop over hours to days, especially in the setting of worsening depression or psychosis.
How is catatonia diagnosed?
Catatonia is diagnosed clinically when a patient shows at least three of the recognized motor signs (such as stupor, waxy flexibility, mutism, negativism, or posturing), often assessed with the Bush-Francis Catatonia Rating Scale. A lorazepam challenge that produces rapid improvement strongly supports the diagnosis. Labs, EEG, and imaging are used to find the underlying medical or neurologic cause, not to diagnose catatonia itself.
Is catatonia curable?
Yes, catatonia itself is usually fully reversible with prompt treatment, typically benzodiazepines and, if needed, electroconvulsive therapy. Most patients recover substantially within days to weeks once treated and the underlying cause is addressed. Long-term outlook depends more on the underlying psychiatric or medical condition than on the catatonic episode itself.
Catatonia vs neuroleptic malignant syndrome — what is the difference?
Both present with rigidity, fever, and autonomic instability, but neuroleptic malignant syndrome specifically follows antipsychotic exposure and classically shows lead-pipe rigidity with poor response to benzodiazepines, usually requiring dantrolene or bromocriptine. Catatonia can occur without any drug trigger, shows waxy flexibility and mutism, and typically responds well to a lorazepam challenge. Malignant catatonia and NMS overlap substantially and can be difficult to distinguish clinically.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F20.2
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.